Growth is primarily driven by the transition toward precision oncology, advancements in molecular diagnostics, and the increasing incidence of gastroenteropancreatic and carcinoid tumours. Additionally, innovations in radiopharmaceuticals, such as Peptide Receptor Radionuclide Therapy (PRRT), and expanded R&D investments by biopharma companies are significantly propelling the market forward.
Peptide Receptor Radionuclide Therapy (PRRT) is a cornerstone of the market. It is highly valued for its ability to deliver targeted radiation directly to tumour cells by binding to somatostatin receptors while sparing healthy tissue. This therapy has gained significant clinical validity for improving survival outcomes and quality of life in patients with advanced or inoperable disease.
The market faces significant barriers related to affordability and infrastructure. High treatment costs for PRRT and immunotherapies, complex manufacturing processes for radiopharmaceuticals, and stringent regulatory requirements for handling isotopes make these advanced treatments difficult to access in low- and middle-income economies.
There is a structural shift toward biomarker-driven platforms and high-sensitivity imaging, such as Gallium-68 PET scans and somatostatin receptor imaging. These technologies allow for earlier and more precise tumour localization, which is critical since NETs are often underdiagnosed or diagnosed late due to non-specific clinical symptoms.
Gastroenteropancreatic (GEP) neuroendocrine tumours dominate the market applications. This is due to their high prevalence compared to other NET types and significant advancements in GEP-specific diagnostic capabilities and therapeutic inventions, such as somatostatin analogues and targeted PRRT.
North America is the market leader, supported by high R&D expenditures, a robust healthcare infrastructure, and early adoption of advanced therapies like PRRT. The presence of major players like Novartis and Pfizer, combined with supportive orphan drug policies and extensive clinical trial activity, strengthens its dominant position.
The Asia-Pacific region is the fastest-growing market. This growth is fueled by rising cancer awareness, healthcare reforms, the expansion of diagnostic facilities in countries like China and India, and increasing partnerships between local entities and multinational pharmaceutical firms.
In early 2025, Novartis expanded its Lutathera portfolio in Japan, and Advanced Accelerator Applications announced a USD 220 million investment to expand radiopharmaceutical manufacturing in Italy. Additionally, Pfizer collaborated with Thermo Fisher Scientific on a biomarker-driven diagnostic platform, and companies like Roche and Bristol-Myers Squibb reported promising data on immunotherapy combination regimens.
AI is reconfiguring the market through digital therapeutics and clinical decision-making systems. AI-powered diagnostics enhance tumour profiling and predictive therapeutic decision-making, while adaptive dosing algorithms and real-time tumour tracking are ushering in a new era of treatment precision and personalized oncology care.
